Abstract-Obstructive sleep apnea is associated with increased cardiovascular morbidity and mortality. We investigated myocardial perfusion using real-time quantitative myocardial contrast echocardiography with concurrent assessment of macrovascular and microvascular endothelial dysfunction in normotensive subjects with moderate-to-severe obstructive sleep apnea, who were compared with hypertensive and healthy subjects, as well as the impact of continuous positive airway pressure treatment on obstructive sleep apnea subjects. We measured flow (hyperemia)-mediated dilation and response to glyceryl trinitrate of brachial artery (ultrasound), cutaneous perfusion responses to acetylcholine and sodium nitroprusside (laser Doppler), pulse wave velocity, and circulating endothelial and endothelial progenitor cells in a total of 108 subjects (nϭ36 each of matched obstructive sleep apnea, hypertension, and healthy cohorts). 
O bstructive sleep apnea (OSA) is associated with several cardiovascular disorders and increased morbidity/mortality. 1 The precise causative mechanism(s) remains uncertain, although attention has been directed toward impaired endothelial function in these patients. 2, 3 Endothelial dysfunction (ED) is central to the pathogenesis of cardiovascular disorders. 1, 4 Various techniques, such as flow-mediated dilatation (FMD), pulse wave analysis, pulse wave velocity (PWV), and laser Doppler flowmetry, have been used to evaluate macrovascular and microvascular endothelial function. [5] [6] [7] [8] More recently, circulating endothelial cell (CEC) and endothelial progenitor cell (EPC) counts have been suggested as surrogate markers of the endothelial damage and repair, 9,10 respectively.
A number of studies have evaluated endothelial function in OSA. [11] [12] [13] [14] [15] [16] [17] Although they generally show abnormalities in the different aspects of endothelial function in OSA, the results show substantial variability, often with controversial findings. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] This may be because of the concomitant confounding factors known to influence endothelial function independent of OSA. Also, myocardial blood flow reserve (MBFR) is a well-validated surrogate marker of coronary perfusion and provides an estimation of coronary flow reserve. Myocardial contrast echocardiography, which uses intravenous contrast agents, has been shown in experimental and human models to be accurate in assessing myocardial perfusion. 21, 22 Continuous positive airway pressure (CPAP) is standard treatment in OSA. Improvement of endothelial function with CPAP treatment in the general OSA population has also been documented, raising the question of its potential impact on myocardial circulation. However, the only available study on the effects of CPAP on myocardial perfusion in OSA appears to be underpowered. 23 In this study, we evaluated different aspects of endothelial function and myocardial perfusion in moderate-to-severe OSA patients free of associated comorbidities. We also studied the effects of CPAP therapy on the study parameters. We tested the hypothesis that subjects with moderate-tosevere OSA would have abnormal perfusion and macrovascular/microvascular indices of ED compared with matched "disease controls: (hypertensives without OSA) and healthy subjects. Finally, we tested the hypothesis that CPAP would reverse macrovascular/microvascular abnormalities in OSA, where present.
Methods
We recruited 36 subjects with a confirmed diagnosis of moderatesevere OSA (apnea-hypopnea index Ͼ15 diagnosed by multichannel polysomnography; FSI Gray Flash recorder, Stowood Scientific Instruments Ltd, Oxford, United Kingdom), from the sleep laboratory in City Hospital Birmingham (Birmingham, United Kingdom). These subjects were compared with 36 matched "disease controls" and 36 "healthy controls," who were recruited from hypertension clinic and community, respectively. OSA was excluded from both control groups (apnea-hypopnea index Ͻ5) using multichannel sleep study. All of the study participants were deemed otherwise healthy by careful history, clinical examination, baseline blood tests, 12-lead ECG, and transthoracic echocardiography (Phillips iE33 ultrasound machine Bothel, WA). We carefully excluded patients with preexisting confounding factors, such as diabetes mellitus, hyperlipidemia, coronary artery disease, known structural heart disease, left ventricular dysfunction, previous cerebrovascular event, malignancy, connective tissue or inflammatory disease, chronic infection, and hepatic or renal impairment. None of our OSA patients were known hypertensive or receiving antihypertensive medications when studied. Ethical approval was granted by the local research ethics committee, and written informed consent was obtained from all of the participants.
All of the study subjects fasted for 12 hours and abstained from smoking, alcohol, tea, and coffee for 24 hours before the study. Hypertensive subjects were advised to omit their medications on the study day, because prolonged treatment omission was deemed unethical. All of the scans were performed in a quiet, darkened, temperature-controlled room after the patient rested for 15 to 20 minutes. Blood pressure (BP) measurement and baseline venous blood sampling were performed before any scanning, from the left and right arm, respectively, while subjects were rested in the supine position.
After baseline measurements, the OSA subjects were autotitrated with an automated CPAP device before being issued with a fixedpressure CPAP (REMstar Pro M Series with C-Flex, Phillips Respironics, PA). CPAP compliance was monitored/recorded throughout the study at regular intervals. Satisfactory CPAP compliance was defined as a minimum usage of 4 hours per night for Ն75% of the week's nights (ie, Ͼ5 nights per week). After a mean duration of 26 weeks on CPAP therapy, all of the available OSA subjects were followed up.
Transthoracic and Myocardial Contrast Echocardiography
Septal wall thickness, posterior wall thickness, and left ventricular mass index (all obtained on M-mode) were used to assess left ventricular structural parameters on transthoracic echocardiography. 24 A microbubbles echocontrast (SonoVue, Bracco Imaging, Milan, Italy) was administered at the rate of 0.7 to 1.0 mL/min (VueJect infusion pump BR-INF 100, Bracco Imaging, Milan, Italy). Real-time destruction replenishment images were acquired in the apical 4-, 3-, and 2-chamber views at rest by a commercially available system (Philips iE33). After a high mechanical index destruction pulse sequence, images were acquired for 15 consecutive frames and stored digitally. All of the patients were then infused with dipyridamole (0.56 mg/kg over 4 minutes) followed by readministration, intravenous contrast, and acquisition of stress contrast images. Offline quantitative myocardial contrast echocardiography analysis was performed by a single observer using standard commercial software (Q-Laboratory, Philips Medical Systems). 21 Basal segments, segments with poor image quality, and frames showing wide variations in contrast intensity were excluded from analysis. Plateau myocardial contrast intensity (A), representing myocardial blood flow volume; the rate of rise of signal intensity (␤), representing mean myocardial blood flow velocity; and their product, myocardial blood flow (Aϫ␤) at rest (FR) and after stress (FS) were measured, enabling calculation of mean MBFR (ratio of FS:FR) for each subject. The interobserver and intraobserver variability in our laboratory (nϭ10) was Ͻ10% for this technique. 
Flow-Mediated Dilatation
The images were acquired with a GE Vingmed System 5 ultrasound system using a hand-held 10-MHz vascular ultrasound probe as per the international guideline. 25 Right brachial artery was scanned using a high-resolution ultrasound probe 3 to 5 cm above the antecubital fossa. Anterior to posterior wall diameters (leading edge to leading edge) were recorded synchronized by R-wave on ECG. Response to flow-mediated hyperemia was assessed to determine endotheliumdependent dilation. For this, the sphygmomanometer cuff was placed around the right upper arm and inflated above the systolic BP for 4.5 minutes, followed by prompt deflation and recording of brachial artery image for 5 minutes. After the baseline brachial artery diameter and flow were restored, 3 minutes after administration of 0.4 mg of glyceryl trinitrates (Nitrolingual, Hohenlockstedt, Germany), endothelium-independent dilation was assessed. Endothelial responses were calculated as percentage of the brachial diameter changes compared with baseline levels. Interobserver and intraobserver variability for the technique (nϭ10) in our laboratory was 2.7% and 1.9%, respectively.
Laser Doppler Flowmetry
Assessment of microvascular endothelial function was performed using scanning laser Doppler flowmeter (Periscan System PIM II, Perimed AB, Stockholm, Sweden, 780 nm red laser) with iontophoresis (0.1 mA for 60 seconds) of 2% acetylcholine (ACH; to evaluate endothelial-dependant response) and 1% sodium nitroprusside (to evaluate endothelium-independent response). 18 In this technique, the current was delivered through 2 drug delivery chambers (model LI 611, Perimed, Jarfalla, Sweden), which were placed on the ventral aspect of the right upper forearm 5 cm apart and were connected to a current intensity-regulated generator (Perilont, Perimed AB). Mean baseline perfusion, mean maximum perfusion, and maximum percentage of change in perfusion were calculated using modern Perimed software. Interobserver and intraobserver variability for the technique (nϭ10) in our laboratory was 6.3% and 8.0%, respectively.
Detailed methods for pulse wave analysis, PWV, and flow cytometry are provided in the online Data Supplement (please see http://hyper.ahajournals.org).
Statistical Analysis and Power Calculation
Data are expressed as meanϮSD for normally distributed data or median and interquartile range for descriptive and/or nonnormally distributed data. Data among 3 groups (OSA, hypertensive, and healthy controls) were analyzed by 1-way ANOVA or KruskalWallis test depending on distribution, whereas paired t test or Wilcoxon test was used for paired analysis. A post hoc Tukey test was performed to assess intergroup differences (with log transformation where appropriate). Pearson correlation was used for normally distributed data, whereas nonnormally distributed data were log transformed before the correlation analysis. A value of PϽ0.05 was considered statistically significant.
On the basis of our previous work on the study parameters (CECs, arterial stiffness, and endothelial damage/dysfunction) we calculated that a sample size of 35 patients in each group would have an 80% power to detect a significant difference. 26, 27 This would be adequate to compare abnormalities of MBFR and ED and would allow correlations to be performed.
Results
Study subjects were comparable in age, sex, and body mass index among the 3 groups ( 
Transthoracic and Myocardial Contrast Echocardiography
The left ventricular structural parameters (ie, septal thickness, posterior wall thickness, and mass index) were similar between OSA and normal controls but were significantly higher in hypertensives (Table 3) . Prestress "A" was significantly attenuated in OSA patients compared with healthy (Pϭ0.01) and hypertensive (PϽ0.05) subjects. This parameter did not differ between hypertensive and healthy subjects. Prestress "␤" was markedly lower in OSA (PϽ0.001) and hypertensive patients (PϽ0.001) compared with healthy controls but was not significantly different between OSA and hypertension groups (Pϭ0.11; Table 3 ). FR was significantly attenuated in OSA and hypertensive subjects compared with the healthy group (both PϽ0.001) but was not significantly different between OSA and hypertensive cohorts (Pϭ0.07; Table 4 ).
After intravenous dipyridamole challenge, the poststress "A" was significantly impaired in OSA compared with healthy subjects (PϽ0.001) and hypertensive patients (Pϭ0.01). Values for "␤," FS, and MBFR were significantly impaired in both OSA and hypertensive groups (both PϽ0.001 versus healthy controls) but did not differ between OSA and hypertensive cohorts (Pϭ0.62 for ␤, 0.24 for FS, and 0.87 for MBFR; Table 5 and Figure 1 ). After 6 months of CPAP therapy, a significant increase was noted in the prestress and poststress segmental "A," "␤," FR, FS, and MBFR (PϽ0.001) compared with pretreatment values (Table  5 and Figure 2 ).
Flow-Mediated Dilatation
Both endothelial-dependent (hyperemia-mediated) and endothelial-independent (glyceryl trinitrates-mediated) dilation of Baseline brachial artery diameter, brachial artery was significantly impaired in OSA and hypertensive groups (all PϽ0.001 versus healthy subjects; Table  6 ). No significant difference in the vascular responses was found between the OSA and hypertensive groups (hyperemic response, Pϭ0.56; glyceryl trinitrates-induced response, Pϭ0.68; Table 6 ). Both endothelial-dependent and -independent responses improved significantly after CPAP therapy (both PϽ0.001; Table 7 ).
Laser Doppler Flowmetry
The response of cutaneous blood flow to iontophoresis of both ACH and sodium nitroprusside was significantly impaired in OSA and hypertensive groups compared with healthy individuals (both PϽ0.001), with no significant difference between the OSA and hypertensive groups (Pϭ0.71 and Pϭ0.23, respectively; Table 8 ). Post-CPAP, endothelial-dependent (Pϭ0.005) and endothelialindependent perfusion increased significantly (Pϭ0.025; Table 9 ).
Pulse Wave Analysis and PWV
No differences were observed in the cross-sectional part of the study in the indices of arterial stiffness between the study groups (Table 10 ). Significant changes in aortic augmentation, augmentation index (AIx), and AIx at heart rate of 75 beats per minute were noted after CPAP therapy in OSA subjects (all PϽ0.05), whereas carotid-femoral PWV remained unchanged (Table 11) .
Flow Cytometric Analysis
There were no significant differences between the groups with respect to the absolute numbers of CECs and EPCs, the EPC:CEC ratio (Table 12 ), or after CPAP therapy (Table 13) .
Discussion
In this study we demonstrate for the first time the presence of the systemic abnormalities in endothelial function in otherwise healthy patients with moderate-to-severe OSA, particularly concomitant ED and impaired myocardial perfusion (perhaps reflecting microvascular dysfunction) in OSA, which may lead to increased cardiovascular mortality and morbidity. We have demonstrated that effective CPAP reverses some of these macrovascular/microvascular abnormalities.
OSA is a common condition that affects 4% to 14% of the middle-aged Western population, with even higher prevalence in the elderly and obese population. 28 Evidence from a number of cohort studies indicated that undiagnosed OSA, even in the mild form, is independently associated with increased likelihood of cardiovascular morbidity. Indeed, ED Values are given as medianϮinterquartile range. PϽ0.05 was considered significant. OSA indicates obstructive sleep apnea; HT, hypertension; AA, aortic augmentation; AIx, augmentation index; AIx@75, augmentation index at heart rate of 75 bpm; SEVR, subendocardial viability ratio; PWV, pulse wave velocity.
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could be the pivotal determinant in the development of cardiovascular pathology in OSA. [11] [12] [13] [14] [15] [16] [17] [18] [19] However, despite well-recognized endothelial abnormalities of large peripheral arteries in OSA patients, scarce data are available on the complex nature of vascular/endothelial function in otherwise healthy patients with moderate-tosevere OSA. In this study, we show for the first time that, in OSA, ED assessed at the macrocirculatory and microcirculatory beds parallels with the impairment of cardiac endothelial function/perfusion. Indeed, myocardial perfusion with myocardial contrast echocardiography has never been studied previously in OSA, in conjunction with other indices of ED. Although we directly estimated abnormalities in myocardial perfusion in our study, Drager et al 19 evaluated carotid intima thickness, a surrogate for atherosclerosis in their study. The induction of OSA in the presence of ED could induce prominent dysregulation of the coronary circulation, indicating an important role for vascular endothelium in the coronary flow dynamics. 29 Notably, a postapneic rise in blood flow is vital to maintain adequate myocardial tissue oxygenation in the face of increased myocardial energy demand and arterial hypoxia. 30 -32 The mismatch between blood flow and maximum oxygen demand, perhaps because of augmented vascular resistance, could lead to postapneic nocturnal myocardial ischemia and angina in patients with OSA, especially in those with concomitant coronary artery disease. 30 -33 In our study, left ventricular structural parameters would not have influenced differences in myocardial perfusion observed between OSA and normal controls, because they were no different.
Abnormalities of FMD have been uniformly demonstrated in a number of disease states and OSA, 5, 11, 12, 34, 35 although previous OSA studies have concomitant confounding cardiovascular risk factors. 11, 12 In the present study, we report FMD abnormalities that improved promptly after CPAP therapy, in normotensive OSA subjects. In contrast, data on the microvascular endothelial function in OSA are more limited. For example, Trzepizur et al 15 reported impaired ACH-induced endothelial (dependent) response in OSA, which improved after 2 months of CPAP therapy. Another small laser Doppler flowmetry study found preserved ACH-mediated microcirculatory responses in OSA subjects. 18 In the present study we observed reduced reactivity to endothelium-dependent (ACH) stimuli, which recovered after CPAP therapy.
We have demonstrated for the first time impaired yet reversible (with CPAP) endothelial independent responses in moderate-to-severe OSA, using FMD and laser Doppler flowmetry. Smooth muscle abnormalities, subclinical inflammatory processes, and vascular remodeling have been postulated as mechanisms responsible for impaired endothelial independent responsiveness in OSA. 36 -38 For example, upregulation interleukin 1␤, interleukin 6, and tumor necrosis factor-␣, may impair endothelial-dependent, as well as -independent, vascular reactivity. 36 Previous studies indicated increased arterial stiffness in OSA. 13, 16 In this study, we found that normotensive moderate-to-severe OSA patients have preserved arterial elasticity as assessed both by PWV and AIx. Although the baseline AIx was preserved in OSA patients, improvements in AIx parameters were noted after CPAP therapy. This observation is consistent with previous reports on CPAP-led improvement in vascular function in OSA and may reflect the parallel reduction in the BP and improvement in endothelial status observed in our study patients. 17, 19 The lack of difference between hypertensive and healthy subjects is likely to reflect relatively mild and adequately controlled hypertension in our study population.
In the last decade, CECs and EPCs have emerged as valuable markers of the endothelial damage and repair. 9 Our study does not show any difference in EPCs and CECs among the 3 groups, with no changes seen after CPAP therapy, consistent with a small study by Martin et al. 14 Although some discrepancy exists in terms of the relation of the circulating endotheliocytes and their progenitors, it is likely to reflect lack of uniform definition of these cells in the circulation, and apparently different subsets of these cells were analyzed by different authors. 39, 40 
Limitations
As an open study, our results are relevant to human health, health risk stratification, and disease management. Nonetheless, CPAP was not randomized, and no control (ie, non-OSA) group was treated with CPAP (which would be clinically unjustified) or restudied longitudinally. One small study with CPAP randomization using cardiac magnetic resonance to estimate MBFR demonstrated similar results in coronary perfusion after CPAP treatment. 41 Another limitation of our study is that, despite using strict inclusion and exclusion criteria, the mean systolic BP in the OSA group was 141 mm Hg. Therefore, the possibility of masked hypertension cannot be excluded altogether, especially because we did not have 24-hour ambulatory BP recordings in this group. 42 However, multiple previous BP recordings, which included community, specialized clinics, and home readings, were in the normotensive range for this group. Moreover, none of these patients demonstrated chamber hypertrophy either on echocardiography or electrocardiography. Therefore, the possibility of masked hypertension is small, and the mildly elevated BP on the day of test in this group does not alter the interpretation of our study results. We also noted improvements in BP and numerous other endothelial function parameters in the OSA group, and, therefore, it is not possible to comment on the precise mechanism(s) of improvement in MBFR after CPAP. We did not record Doppler flow velocities while performing the FMD studies; therefore, it is possible that changes observed during the test may reflect changes in flow rather than endothelial function. Also, the baseline brachial diameter was lower (not statistically) in the control subjects, and this may have accounted for some of the difference between the FMD for the 3 groups. 42 However, previous studies have shown that vessels with diameter between 2.5 and 5.0 mm (as in our study) produce consistent results on FMD independent of their original diameter, and, thus, the baseline brachial diameter differences do not significantly alter the interpretation of our study results. 43, 44 Perspectives Concomitant ED and impaired myocardial perfusion (reflecting microvascular dysfunction) are present in otherwise normal subjects with moderate-to-severe OSA, which may lead to increased cardiovascular mortality and morbidity in such patients. Effective CPAP reverses many of these macrovascular/microvascular abnormalities.
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None. Sphygmocor device (Sphygmocor, Atcor medical, Sydney, Australia) was used to measure the PWA and PWV. We recorded baseline carotid arterial waveforms non-invasively over 10 seconds using a high-fidelity hand-held applanation tonometer. Aortic augmentation [AA], aortic augmentation index [AIx], aortic augmentation index corrected for heart rate of 75 beats per minute [AIx@75] and sub-endocardial viability ratio [SEVR]) were derived using an inbuilt modern Sphygmocor CVMS software system (Version 8). Aortic PWV was recorded by making sequential ECG-gated tonometer recordings at the carotid and the femoral arteries. Inter-and intra-observer variability for the technique (n=10) in our laboratory was 10% and 5.1% respectively.
Flow Cytometry
A fasting venous blood sample was taken from the right antecubital vein into EDTA vacutainers. Within three hours of sampling quantification of EPCs and CECs were performed using flow cytometry (FACSCalibur, Becton Dickinson, Oxford, UK). Full blood count was obtained using a hematoanalyser (Advia, Bayer). 200ul of whole EDTA-anticoagulated venous blood mixed with 500ul of phosphate buffer solution (PBS) was incubation with fluorochrome-labeled monoclonal antibodies anti-CD45-PerCP (Becton Dickinson, Oxford, UK), anti-CD34-PE (Becton Dickinson, Oxford, UK), anti-CD146-FITC (Biocytex, France) and KDR-PE (R&D, UK) for 20 minutes in the dark at room temperature. The sample was then lysed with BD lysing solution® (Becton Dickinson, Oxford, UK) and washed once in PBS. The resultant pellet was then re-suspended in PBS before running for flow cytometric analysis. Acquired events were plotted according to their forward and side scatter characteristics and gated to include mononuclear cell events. EPCs were defined as CD34+/KDR+ events and CECs as CD34+/CD146+ antibodies. A minimum of 1,000,000 mononuclear cellular events was analyzed per sample. Absolute count of EPCs and CECs was obtained using their proportion to CD45+ leukocytes and leukocyte count from whole blood analysis. This technique gave us 10-20% interand intra-observer variability.
